Haixin Biotechnology Co. Ltd   Report issue

For profit Phase 3
Founded: Shanghai China (1986)
Status: No NME R&D (1986)

Organization Overview

First Clinical Trial
2015
NCT02503150
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colorectal Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 4